^
    Back
    Association details:
    Biomarker:TP63 rearrangement
    Cancer:Lymphoma
    Drug:Ezharmia (valemetostat) (EZH2 inhibitor, EZH1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Sci Transl Med
    Title:

    TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence

    Published date:
    09/20/2023
    Excerpt:
    One patient with TP63-rearranged lymphoma showed a rapid response to valemetostat treatment….Our findings suggest that patients with lymphoma with TP63 rearrangements might respond to valemetostat…
    DOI:
    10.1126/scitranslmed.adi724